Drugs that contain Donepezil Hydrochloride; Memantine Hydrochloride
1. Namzaric patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
|
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
| US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8173708 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8283379 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8338486 | ABBVIE | Methods for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8580858 | ABBVIE | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8329752 | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8168209 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8598233 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8293794 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8338485 | ABBVIE | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
|
US8598233 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8283379 (Pediatric) | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
|
US8173708 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8362085 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8168209 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8329752 (Pediatric) | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
| US8039009 | ABBVIE | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(4 years from now) | |
|
US8039009 (Pediatric) | ABBVIE | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) | |
| US8058291 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(5 years from now) | |
Market Authorisation Date: 18 July, 2016
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC family patents
